Skip to main content

Table 1 The baseline characteristics of included studies

From: Meta-analysis of the potential role of extracorporeal shockwave therapy in osteonecrosis of the femoral head

Study Year Study year ONFH stage Study style Group Number/hips Gender (M/F) Age (year) Duration (month)
Wang CJ 2012 2001–2001 Stages I, II, early III Non-RCT ESWT 23/29 20/3 39.8 ± 12.1 25.2 ± 3.7
Surgical group 25/28 22/3 39.9 ± 9.3 25.8 ± 4.6
Chen JM 2009 1999.7–2006.1 Stages I–III Non-RCT ESWT 17/17 14/3 42.9 ± 9.3 11.3 ± 3.4
Stages I–IV THA 17/17 14/3 42.9 ± 9.3 14.7 ± 0.93
Zhang HJ 2015 2009.1–2012.12 Stages I–II RCT BMSC+ESWT 20/29 15/5 36.1 ± 6.2 24
BMSC 20/27 14/6 35.5 ± 5.7 24
Zhai L 2008 1998.1–2007.6 Stages I–III Non-RCT CD + ESWT 50/50 41/9 20.9(18–25) 6.4(3–18)
CD 58/58 45/13 20.5(18–25) 7.3(3–20)
  1. ESWT extracorporeal shock wave treatment, THA total hip arthroplasty, CD core decompression, M/F males/females, RCT randomized controlled trail, ONFH osteonecrosis of the femoral head, THA total hip, BMSC bone marrow stem cells